Table 3.
Comparison of Commonly Prescribed Buprenorphine Products
| Trade Name | Generic Name | Route | FDA Indication | X-Waiver Required? | Starting Dose |
|---|---|---|---|---|---|
| Butransa | Buprenorphine | Transdermal patch | Chronic pain | No | 5ug/hr week |
| Belbucab | Buprenorphine | Buccal tablet | Chronic pain | No | 75ug once daily |
| Suboxonec | Buprenorphine-naloxone# | Sublingual film or tablet | Opioid use disorder | Yes* | 2mg-0.5mg |
| Subutexc | Buprenorphine | Sublingual tablet | Opioid use disorder in patients who cannot tolerate naloxone | Yes | 2mg |
a
Purdue Pharma L.P., Stamford, CT, USA
b
BioDelivery Sciences International, Inc, Raleigh, NC, USA
c
Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA, USA
#
When taken sublingually, the effect of buprenorphine predominates; if injected however, the effect of naloxone predominates.
*
No X-waiver needed if used off-label for treatment of pain [125]